信达生物在2025年ASCO年会上公布,其创新型药物IBI343在治疗CLDN18.2表达阳性的晚期胰腺癌患者中展现出优秀治疗潜力,已获NMPA和FDA认定。最新研究数据显示,该药物在83例胰腺癌患者中表现出良好的疗效和安全性。
Source Link信达生物在2025年ASCO年会上公布,其创新型药物IBI343在治疗CLDN18.2表达阳性的晚期胰腺癌患者中展现出优秀治疗潜力,已获NMPA和FDA认定。最新研究数据显示,该药物在83例胰腺癌患者中表现出良好的疗效和安全性。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.